IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Keith Biggadike et al.

Serial. No.: 10/533,168

International Filing Date: October 30, 2003

Confirmation No.: 9215

Title: Phenylethanolamine Derivatives for the Treatment of Respiratory

Diseases

COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, VA 22313-1450

PETITION TO WITHDRAW NOTICE OF ABANDONMENT

Sir:

This paper is in response to Notice of Abandonment dated January 22, 2008.

REMARKS

A Notification of Abandonment stating the reason for abandonment as "failure to respond to the notification of MISSING REQUIREMENTS mailed March 8, 2006 within the time period set therein."

Applicants attach herewith a copy of the Response to Notification of Missing Requirements filed by facsimile on March 29, 2006 along with the facsimile confirmation and Auto Reply Facsimile Transmission. Such a response was clearly timely.

Applicants submit that the Notice of Abandonment was in error.

Accordingly, such a Notice should be withdrawn and the application forwarded to an Examiner for examination.

Respectfully submitted,

/Robert J. Smith/ Robert J. Smith Attorney for Applicant Registration No. 40,820

Date: January 24, 2008
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive

Five Moore Drive P.O. Box 13398

Research Triangle Park, NC 27709-3398

Phone: 919-483-9616 Facsimile: 919-483-7977

Enclosures:

- Applicants' response to Notification of Missing Requirements
- 2) Auto Reply Facsimile Transmission

USPTO 3/29/2006 2:24 PM PAGE 1/001 Fax Server D: Auto-reply fax to 919 483 78 COMPANY:

Auto-Reply Facsimile Transmission



TO: Fax Sender at 919 483 7977

Fax Information

Date Received: 3/29/2006 2:18:50 PM [Eastern Standard Time]

Total Pages: 19 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seg.

Received Cover Page

Fax				GlazoSmithKšne	
Ϋ́	DO/ED/US			SterroStrotostano	
Compos	ey USPTO			PO Bloc 19098 Fine Moore Drivo	
Fax	571-273-3001			Roseer's Troopin Fort North Curron 27782	
r rom	Petricie Vesson		· ·	Tel: (218 45) (2140) provinces room	
Tes		simila: 1-915-483-7896	•••		
E-reait	patricia t sistem@gas	coom			
Deto	Nestect: 78, 2006	Pages including asyar	9		
		ton of Missing Requirements			
	Adoxney Docket No. 2G	rine Derivelines for the Troutine 53198w	оп от Невригору С	2608596C	
1 7	Transmittal Lotter	(in duplicate)			
2 8	Deciseation				
		issing Requirements under 35 L		es 3/8/2006	
		hange of Correspondence Audi	80%		
	Statemen: under 3 73(b) Corporate Resolution				
	•	illuste of Temerals should be Faced	nile (ST CFR 1.8)		
insens see	erithy that this <u>Response</u> size Patent and Traspenses A4 LJ LJ LJ Patry William	RR Notification of Minima Non-insec Office (Fee. No. 2713/3-2001)	nents is being to Disc Attends tig	esianta tronsmituri to the	
recipions of	hir displacese, regressions, of	ne rice to conflicionales source poblem (en pri el distribution decisions or the employe encountry, or any colors sissues or adopts or metallicity of the colors of the colors of the property of the colors of the	e or agend necessaries	to deliver 3 to the intended	

Message Confirmation Report

MAR-29-2006 02:30 PM WED

Fax Number

: 919 483 7977

Name

GSK

Name/Number

915712733201

Page

19

2

Start Time

MAR-29-2006 02:24PM WED

Elapsed Time Mode

2 05'19" ŝ

Results

STD ECM [O. K]

FAX

20

FZZ

From

GlaxoSmithKline DO/EO/US **GiscoSmithniting** PO Box 13398 Company USPIO Five Moore Cirke Research Triengle Park North Cereine 27708 871-273-3201 Tel: 919 483 2100

Patricia Wilson Tel 1-919-483-1007; Facsimile: 1-919-483-7988

E-mail patricia.t.wilson@gsk.com Date March 28, 2006

Pages including cover 17

Subject Response to Notification of Missing Requirements

Re:

Serial No.: 10/533,168; Int'L Appl. No.: PCT/EP03/12161
Title: Phenylethanolemine Derivatives for the Treatment of Respiratory Diseases Attorney Docket No. PG5019Sw

Attached is:

- 1 Transmittal Letter
 - (in duplicate)
- 2. Declaration
- 3. Copy of Notification of Missing Requirements under 35 USC 371, date mailed 3/6/2006
- A Power of Attorney and Change of Correspondence Address
- 5, Statement under 3,73(b)
- 6. Corporate Resolution

Certificate of Transmission by Faceimite (37 CPR 1.8)

I hereby certify that this <u>Response to Notification of Missing Regularoments</u> is being facsimile transmitted to the United States Patent and Trademork Office (Fex. No. 671-273-3201] on <u>March 39, 2006</u>

Baffy Wild

The information contained in these documents is confidential and may also be privileged and is intended for the anotherina use of the addresses designated above. If you are not the intended recipient or the amplitude or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

FAX



To	DO/EO/US	Olava Osadish Schina				
**********	\$	GlaxoSmithKline PO Box 13398				
Comp	any USPTO	Five Moore Drive Research Triangle Park				
Fax	571-273-3201	North Carolina 27709				
From	Patricia Wilson	Tel: 919 483 2100 www.gsk.com				
Tel	1-919-483-1007; Facsimile: 1-919-483-7988					
E-mail	patricia.t.wiison@gsk.com					
Date	March 29, 2006 Pages including cover 19					
Subjec	t Response to Notification of Missing Requirements					
Re:	Application of Biggadike et al.					
	Serial No.: 10/533,168; Int'l. Appl. No.: PCT/EP03/12161 Title: Phenylethanolamine Derivatives for the Treatment of Respiratory Dis					
	Title: Phenylethanolamine Derivatives for the Treatment of Respiratory Dis Attorney Docket No. PG5019Sw	:08S 0 S				
Attache	ed is:					
1.	Transmittal Letter (In duplicate)					
2.	Declaration					
3.	Copy of Notification of Missing Requirements under 35 USC 371, date mailed 3/8/2006					
4.	Power of Attorney and Change of Correspondence Address					
5.	Statement under 3.73(b)					

Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this <u>Response to Notification of Missing Requirements</u> is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>571-273-3201</u>) on <u>March 29, 2006</u>.

Patty Wilson

Corporate Resolution

G.

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

FORM	PTO-13	90 (Modified) U.S. PATENT AND TRADESS	ARK OFFICE; U.S. DEPARTMENT OF COMMERCE	ATTORNE: DOCKET NUMBER					
(KEV. 1	TR	ANSMITTAL LETTER T	PG5019USw						
	Ε	DESIGNATED/ELECTE	D OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)					
C		ICERNING A SUBMISS	10/533,168						
NTE	RNAT	IONAL APPLICATION NO. PCT/EP03/12161	INTERNATIONAL FILING DATE October 30, 2883	PRIORITY DATE CLAIMED November 1, 2002					
TITLE	ITLE OF INVENTION								
PHE	PHENYLETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES								
				7					
		T(S) FOR DO/EO/US							
Keith	BIG	GADIKE, Keith BLAKE, Diane	Mary COE, Duncan Stuart HOLMES, Pa	anayiotis Alexandrou PROCOPIOU					
Applic	ant h	erewith submits to the United State	s Designated/Elected Office (DO/EO/US) the	following items and other information:					
1.		This is a FIRST submission of iter	ns concerning a submission under 35 U.S.C.	. 371.					
2.	Ø		ENT submission of items concerning a submi	§					
3.				C. 371(f)). The submission must include items (5), (6),					
4.		The US has been elected (Article	31).						
5.		A copy of the International Applica	ation as filed (35 U.S.C. 371 (c)(2))						
		a. is attached hereto (requi	red only if not communicated by the Internat	tional Bureau).					
	b. has been communicated by the International Bureau.								
		c. Is not required, as the application was filed in the United States Receiving Office (RO/US).							
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).							
		a. 🔲 is attached hereto.							
		b. has been previously sub	mitted under 35 U.S.C. 154(d)(4).						
7.			International Application under PCT Article 19	8					
			uired only if not communicated by the Interna	ational Bureau).					
			d by the International Bureau.						
			wever, the time limit for making such amends	ments has NOT expired.					
		d. have not been made and							
8.	l	-	f the amendments to the claims under PCT A	Artide 19 (35 U.S.C. 371(c)(3)).					
9;	X	An eath or declaration of the inver An English language translation of	nor(s) (35 0.5.0. 37 ((5)4)). If the annexes to the International Preliminary	Examination Report under PCT					
		Article 36 (35 U.S.C. 371 (c)(5)).							
11.			nary Examination Report (PCT/IPEA/409).						
12,	L	A copy of the International Search	Report (PCT/ISA/210).						
ite		3 to 23 below concern document	(s) or information included:						
13.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
14.			rding. A separate cover sheet in compliance	with 37 CFR 3,28 and 3,31 is included.					
15,		A FIRST preliminary amendment.		· · · · · · · · · · · · · · · · · · ·					
16.		A SECOND or SUBSEQUENT pre	eliminary amendment.	***************************************					
17.		A substitute specification.	S 124 1-14.	***************************************					
18.	⊠ □	A power of attorney and/or change		40/2 4 27 (50) 1 20 1 505					
19.		· ·	equence listing in accordance with PCT Rule	£					
20.		A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).							
21. 22.		Express Mail Label No.							
mer	Approve that suces the								

PTC-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. CMB 0851-0021
U.S. Patent and Trademark Offici; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATIO	N NO (if known, see :	37 CFR 1.5)	INTERNATIONAL	APPLI	CATION NO.	ATTORNEY'S DOC	KET NUMBER
Ĭ	0/533,168		PCT/EP0	3/12	161	PG50191	Sw
Statement	ns or information: under 37 CFR 3.7. Resolution	3(b)					
The following	fees have been s	obmitted:				CALCULATIONS	PTO USE
	stional fee				\$300	\$ \$0.00	
If the written opini prepared by IPEA	ation fee (37 CFR on prepared by IS	1.492(c)) A/US or the laims satisf)	International preliminar provisions of PCT Art	y exa	mination report \$0 \$200	\$ \$0.00	
26. Search fee (37 CFR 1.492(b)) If the written opinion fihe ISA/US or the International preliminary examination report by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4) \$0 Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the as an international Searching Authority. \$100 International Search Report prepared by an ISA other than the US and provided to the previously communicated to the US by the IB. \$400					\$ \$9.80		
	OF 24, 25 and				\$500	\$ \$0.00	
Additional fer sequence lis listing in an e The fee is \$2	Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.						
- 100 =	0 /50 =		0		× \$250.00	\$ \$0.00	
			earch fee, examination the national stage (37)			\$ \$130.00	
CLAIMS	NUMBER F		NUMBER EXTRA		RATE		
Total claims		- 20 =	Ō	х	\$50.00	\$0.00	
Independent clair	ns	- 3=	()	x	\$200.00	\$ \$0.00	
MULTIPLE DEPE	NDENT CLAIMS	(if applicable	·) []	*	\$360.00	5 50.00	
	***************************************	TOT	AL OF ABOVE CA	ALC!	JLATIONS =	\$ \$130.00	
And and signed signed and the state of Control of Car 27 Car and the state of the s						\$ \$0.00	
SUBTOTAL =						5 \$130.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).					\$ \$9.00	×	
						S \$130.00	
Fee for recording accompanied by	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 pcr property +					\$ 50.00	
			TOTAL FEI	SE	NCLOSED =	\$ 5130.00	
						Amount to be	\$
						Amount to be	S

Und	PTO-1390 (Rev. 07-2005) Approved for use through 3/31/2007. CMB 0651-0021 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.						
a.		A check in the amount of \$ to cover	r the above fees is enclosed.				
b.	X	Please charge my Deposit Account No. 87-1392 A duplicate copy of this sheet is enclosed.	in the amount of \$ \$130.00 to cover the above fees.				
C.	×		additional fees which may be required, or credit any overpayment ate copy of this sheet is enclosed.				
d.		Fees are to be charged to a credit card. WARNING: In Information should not be included on this form. P	ormation on this form may become public. Credit card ovide credit card information and authorization on PTO-2038.				
		Where an appropriate time limit under 37 CFR 1.495 if filed and granted to restore the international Appli	has not been met, a pelition to revive (37 CFR 1.137(a) or (b)) sation to pending status.				
SE	ND A	ALL CORRESPONDENCE TO:					
			SIGNATURE				
			Robert J. Smith				
			NAME				
		23347	40,820				
REGISTRATION NUMBER							
			DATE				
٤							

Connection	200000000000000000000000000000000000000							
FORM	PTO-1 7-2005	390 (Modified) — U.S. PATENT AND TRADEMAR! }	K OFFICE; U.S. DEPARTMENT OF COMMERCE	ATTORNEY'S DOCKET NUMBER				
		RANSMITTAL LETTER TO		2G5019USw				
		DESIGNATED/ELECTED	OFFICE (DO/EO/US)	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)				
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371				19/533,168				
INTE	RNA		NTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED				
TITL	E OF	PCT/EP03/12161 INVENTION	October 30, 2903	November 1, 2002				
			S FOR THE TREATMENT OF RESPI	RATORY DISEASES				
APP	LICAN	(T(S) FOR DO/EO/US						
8:			fary COE, Duncan Stuart HOLMES, Pa	anayiotis Alexandrou PROCOPIOU				
Appli	cant f	erewith submits to the United States E	Designated/Elected Office (DO/EO/US) the	following items and other information:				
1.		This is a FIRST submission of items	concerning a submission under 35 U.S.C.	371.				
2.	M		IT submission of items concerning a submi					
3				. 371(f)). The submission must include items (5), (6),				
4.		The US has been elected (Article 31)).					
5,		A copy of the Infernational Application	on as filed (35 U.S.C. 371 (c)(2))					
		a. is attached hereto (required only if not communicated by the International Bureau).						
		b. has been communicated by the International Bureau.						
		c. D is not required, as the application was filed in the United States Receiving Office (RO/US).						
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).						
		a. 🗌 is attached hereto.						
		b. [] has been previously submitted under 35 U.S.C. 154(d)(4).						
7.		Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))						
		a. are attached hereto (required only if not communicated by the International Bureau).						
		b. have been communicated to	by the International Bureau.					
		c. have not been made; howe	ever, the time limit for making such amendr	ments has NOT expired.				
		d. D have not been made and w						
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).						
9.	S	An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).						
10.		An English language translation of the Article 36 (35 U.S.C. 371 (c)(5)).	ne annexes to the International Preliminary	Examination Report under PCT				
11.		A copy of the International Preliminar	ry Examination Report (PCT/IPEA/409).					
12.		A copy of the International Search Re	eport (PCT/ISA/210).					
lte	ems 1	3 to 23 below concern document(s)	or information included:					
13.		An information Disclosure Statement under 37 CFR 1.97 and 1.98.						
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.						
15.		A FIRST preliminary amendment.						
16.		A SECOND or SUBSEQUENT prelim	ninary amendment.					
17.		A substitute specification.						
18.	\boxtimes	A power of attorney and/or change of	f address letter.					
19.		A computer-readable form of the seq	pence listing in accordance with PCT Rule	13ter.2 and 37 CFR 1.821 - 1.825.				
20.			national Application under 35 U.S.C. 154(d					
21.		A second copy of the English languar	ge translation of the International Application	on under 35 U.S.C. 154(d)(4).				
22.		Express Mail Label No.						

PTC-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO (if known, see 37 CFR 1.5)

U.S. APPLICATION NO (if known, see 37 CFR 1.5)

U.S. APPLICATIO	CATION NO (8 known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO.		ICATION NO.	ATTORNEY'S DOCKET NUMBER				
	10/533,168 PCT/EP03/12161		2161	PG5019USw		USw		
Statemen	ms or information; t under 37 CFR 3.7 e Resolution	(3(b)						
The following	g fees have been s	submitted:				CALCULATI	ONS	PTO USE
24. 🗆 Basic n	ational fee			. ,	\$300	\$	\$0.00	
If the written opin prepared by IPEA	ation fee (37 CFR ion prepared by IS VUS indicates all o s	A/US or the satisfy	international prelimina provisions of PCT Art	ry exi	amination report \$0	\$t7	\$0.00	
26. Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International preliminary examination report by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4). \$0 Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the as an International Searching Authority. \$180 International Search Report prepared by an ISA other than the US and provided to the previously communicated to the US by the IB. \$400					\$9.00			
All other situations \$500 TOTAL OF 24, 25 and 28 =						 S	\$9.00	
Additional fe sequence lis listing in an e The fee is \$2	Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets or paper or fraction thereof.							
- 100 ≈	0 /50 =		0		× \$250.00	S	\$0.00	
			earch fee, examination the national stage (37 t		or the oath or		130.00	
CLAIMS	NUMBER F	LED	NUMBER EXTRA		RATE			
Total claims		- 20 =	0	х	\$50.00	\$	\$0.00	
Independent dain	ns	- 3 =	9	х	\$200.00	\$	\$0.00	
MULTIPLE DEPE	NDENT CLAIMS	if applicable) D	+	\$360.00	\$	\$0.00	
	***************************************	TOT	AL OF ABOVE CA	\LC	JLATIONS =	s s	130.00	
Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.						s	\$0.00	
						<u>s</u>	130.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).					s	\$0.00		
TOTAL NATIONAL FEE =					S 5	130.00		
Fee for recording accompanied by a	the enclosed assign appropriate cov	gnment (37 (er sheet (37	OFR 1.21(h)). The ass OFR 3.28, 3.31). \$40	ignm per p	ent must be property +	s	\$0.00	
			TOTAL FEE	SE	NCLOSED =	s s	130.00	
						Amount to b		S
						Amount to b	10	s

PTC-1390 (Rev. 07-2005)
Approved for use through 3/31/2007, OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. a. A check in the amount of \$ to cover the above fees is enclosed. 97-1392 \$130.00 in the amount of \$ to cover the above fees. b. Please charge my Deposit Account No. A duplicate copy of this sheet is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment . A duplicate copy of this sheet is enclosed. to Deposit Account No. 07-1392 d. [3] Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status. Tobet A SEND ALL CORRESPONDENCE TO: Robert J. Smith NAME 40,820 23347 REGISTRATION NUMBER 3-29-06



United States Patent and Trademark Office

PAI BOS SCHIMAN

UNITED STATES DEPARTMENT OF COMMERC United States Patent and Trademack Office Address COMMISSIONER FOR PATENTS PO. Box 1439

Alexandria, Virginia 22313-1450 Strangento gen

U.S. APPLICATION NUMBER NO.

FIRST NAMED APPLICANT

ATTY, DOCKET NO.

10/533,168

Keith Biggadike

PG5019USw

INTERNATIONAL APPLICATION NO.

PCT/EP03/12161

LA. FILING DATE

PRIORITY DATE

10/30/2003

11/01/2002

23347 GLAXOSMITHKLINE CORPORATE INTELLECTUAL PROPERTY, MAI B475 FIVE MOORE DR., PO BOX 13398 RESEARCH TRIANGLE PARK, NC 27709-3398

MAR 1 5 2006

CONFIRMATION NO. 9215 371 FORMALITIES LETTER

OC000000018197417

Date Mailed: 03/08/2006

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 04/29/2005
- Copy of the International Search Report filed on 04/29/2005
- Copy of IPE Report filed on 04/29/2005
- Preliminary Amendments filed on 04/29/2005
- Information Disclosure Statements filed on 04/29/2005
- U.S. Basic National Fees filed on 04/29/2005
- Priority Documents filed on 04/29/2005
- Specification filed on 04/29/2005
- Claims filed on 04/29/2005
 Abstracts filed on 04/29/2005

The applicant needs to satisfy supplemental fees problems indicated below.

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1,497(a) and (b), identifying the application by the international application number and international filling date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Docket No: PG5019 USW Attorney: RTS/SCH Paper: Beclaration W/ France Due Date: US may 2006 Desdine. OV OCT 2006 Recorded: On Total additional fees required for this application is \$130 for a Large Entity:

\$130 Surcharge.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no, shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

KAYA L LEWIS BALTIMORE

Telephone: (703) 308-9140 EXT 202

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
10/533,168	PCT/EP03/12161	PG5019USw

FORM PCT/DO/EO/905 (371 Formalities Notice)